Nav: Home

Cargo-carrying red blood cells alleviate autoimmune diseases in mice

March 06, 2017

CAMBRIDGE, Mass. (March 6, 2017) - Using red blood cells modified to carry disease-specific antigens, scientists in the laboratories of Hidde Ploegh (former Whitehead Member, currently Boston Children's Hospital) and Harvey Lodish (Whitehead Founding Member) have prevented and alleviated two autoimmune diseases -- multiple sclerosis (MS) and type 1 diabetes--in early stage mouse models.

"This is a very promising step in the development of therapies for autoimmune diseases," says Lodish, who is also a professor of biology and a professor of biological engineering at MIT. "If this type of response is also true in humans, then it could make a lot of these therapies possible for these diseases and similar conditions."

Inappropriate immune responses cause scores of autoimmune diseases -- from rheumatoid arthritis to systemic lupus erythematosus to inflammatory bowel disease -- in which the body destroys its own cells. The National Institutes of Health estimates that autoimmune diseases affect more than 23 million Americans. These conditions are commonly treated with immunosuppressants to keep a patient's overactive immune response in check. However, these drugs also indiscriminately dull the immune response to pathogens.

Using bits of proteins from the offending cells--antigenic peptides -- researchers have retrained the immune system to ignore the antigens that trigger inappropriate immune responses. This method, called tolerance induction, shows promise, but the technique is fraught with problems, including delivering the antigenic peptides to their destination before they are degraded or beset by immune cells.

To sidestep many of these issues, the labs of Lodish and Ploegh have pressed red blood cells into service.

Red blood cells are particularly well-suited for the delivery of molecules throughout the body. Not only do these cells quickly access almost every tissue, they are also recycled every month in mice and four months in humans without triggering an immune response against them. In previous research, the team attached biotin (a chemical tag) and antibodies to red blood cell using a method developed by Ploegh's lab called "sortagging".

The current work, which is described online this week in the journal PNAS, uses cargo-laden red blood cells to intercede in autoimmune diseases. Novalia Pishesha, an MIT Biological Engineering graduate student in the Lodish and Ploegh labs, drew blood from a mouse, used sortagging to decorate the red blood cells with the antigens that trigger the harmful immune response, and transfused the altered red blood cells back into mouse models of type 1 diabetes and MS. The entire process can be completed in about an hour.

In mice, the transfusions reduced symptoms of disease and even a single injection prior to the onset of disease could prevent further symptoms.

Although antigenic peptides can be effective in stimulating the induction of tolerance, the mechanism responsible is not well understood at the cellular and molecular levels.. "Essentially what we're doing is hijacking the red blood cell clearance pathway, such that the foreign antigen masquerades as the red blood cells' own, such that these antigens are being tolerated in the process," says Pishesha, who is also the first author of the PNAS paper.

For Ploegh, the research could lead to future insights into how the immune system regulates itself and how that sometimes goes awry. As a cautionary note, he points out that red blood cells used in the experiment are not "immunologically inert".

"The Kell protein, which we use as an anchor point for many of our modifications, is a blood group antigen, and by its very nature shows that the immune system can distinguish red blood cells from genetically disparate individuals," says Ploegh. "This [technique used by Pishesha] may be an interesting way to explore how the immune system distinguishes self from non-self."
-end-
This work was supported by Defense Advanced Research Projects Agency Contract HR0011-12-2-0015, the Schlumberger Foundation Faculty for the Future, the Howard Hughes Medical Institute, and the Siebel Scholars Foundation.

Harvey Lodish's primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a professor of biology and a professor of biological engineering at Massachusetts Institute of Technology (MIT). Hidde Ploegh, a former Whitehead member, is a Senior Investigator in the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital. Lodish and Ploegh serve as paid consultants and own equity in Rubius, a biotech company that seeks to exploit the use of modified red blood cells for therapeutic applications.

Full Citation:

"Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease"

PNAS, online the week of March 6, 2107.

Novalia Pishesha (1,2,3), Angelina M. Bilate (1), Marsha C. Wibowo (1,4), Nai-jia Huang (1), Zeyang Li (1,3), Rhogerry Dhesycka (1,2), Djenet Bousbaine (1,3,4), Hojun Li (1), Heide C. Patterson (1), Stephanie K. Dougan (1), Takeshi Maruyama (1), Harvey F. Lodish (1,2,4), and Hidde L. Ploegh (1,3,4)

1. Whitehead Institute for Biomedical Research, Cambridge, MA 02142

2. Department of Biological Engineering, Massachusetts Institute of Technology,Cambridge, MA 02142

3. Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115

4. Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142

Whitehead Institute for Biomedical Research

Related Diabetes Articles:

The role of vitamin A in diabetes
There has been no known link between diabetes and vitamin A -- until now.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
Type 2 diabetes and obesity -- what do we really know?
Social and economic factors have led to a dramatic rise in type 2 diabetes and obesity around the world.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
The Lancet Diabetes & Endocrinology: Older Americans with diabetes living longer without disability, US study shows
Older Americans with diabetes born in the 1940s are living longer and with less disability performing day to day tasks than those born 10 years earlier, according to new research published in The Lancet Diabetes & Endocrinology journal.
Reverse your diabetes -- and you can stay diabetes-free long-term
A new study from Newcastle University, UK, has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.
New cause of diabetes
Although insulin-producing cells are found in the endocrine tissue of the pancreas, a new mouse study suggests that abnormalities in the exocrine tissue could cause cell non-autonomous effects that promotes diabetes-like symptoms.
The Lancet Diabetes & Endocrinology: Reducing sugar content in sugar-sweetened drinks by 40 percent over 5 years could prevent 1.5 million cases of overweight and obesity in the UK and 300,000 cases of diabetes
A new study published in The Lancet Diabetes & Endocrinology journal suggests that reducing sugar content in sugar sweetened drinks (including fruit juices) in the UK by 40 percent over five years, without replacing them with any artificial sweeteners, could prevent 500,000 cases of overweight and 1 million cases of obesity, in turn preventing around 300,000 cases of type 2 diabetes, over two decades.
Breastfeeding lowers risk of type 2 diabetes following gestational diabetes
Women with gestational diabetes who consistently and continuously breastfeed from the time of giving birth are half as likely to develop type 2 diabetes within two years after delivery, according to a study from Kaiser Permanente published today in Annals of Internal Medicine.

Related Diabetes Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...